Oscar Health, Inc.
NYSE:OSCRMedical - Healthcare Plans
+$0.05 today
- Market cap
- $7.15B
- Beta
- 2.39
- P/E (TTM)
- -214.2
- EPS (TTM)
- -$0.13
Volume 7.38M
Average 7.51M
OSCR EBITDA Margin
EBITDA as a percentage of revenue.
Oscar Health, Inc.NYSE: OSCR
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 8.1%
EBITDA Margin was 8.1% in Q2 FY2026, up 15.8 pp from a year earlier. On a trailing-twelve-month basis it was 4.1%, up 5.0 pp year over year. Over 3 fiscal years it widened by 10.5 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of 4.6% for the fiscal year ending Dec 2026, up from -3.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 8.1%-7.2 pp QoQ
- Last fiscal yearDec 2025
- -3.3%-4.3 pp YoY
- LTMJun 2026
- 4.1%+5.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.8 pp | +3.4 pp | -12.4 pp |
| 1 year | -4.3 pp | +7.9 pp | +12.2 pp |
| 3 years | +10.5 pp | +7.8 pp | -2.7 pp |
| 5 years | +8.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -3.3%
- Year-over-year change
- -4.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -3.3% | -4.3pp |
| FY2024 | 2024-12-31 | 1.0% | +4.6pp |
| FY2023 | 2023-12-31 | -3.6% | +10.3pp |
| FY2022 | 2022-12-31 | -13.9% | +14.8pp |
| FY2021 | 2021-12-31 | -28.7% | — |
EBITDA Margin vs competitors
How OSCR compares with its peers on the latest reported figures
- OSCR's LTM Jun 2026 EBITDA Margin of 4.1% is the 3rd highest of the 8 companies compared; the peer median is 1.6%.
- Its year-over-year change of +5.0 pp is the highest of 8, against a peer median of -0.4 pp.
- Over three fiscal years its change of +10.5 pp compares with a peer median of -1.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 4.4% | -0.7 pp | -1.6 pp | |
| LTM Sep 2026 | 4.4% | -0.2 pp | -2.1 pp | |
| LTM Jun 2026 | 4.1% | +5.0 pp | +10.5 pp | |
| LTM Jun 2026 | 3.2% | -0.4 pp | -1.4 pp | |
| LTM Mar 2026 | 1.6% | +2.9 pp | +9.1 pp | |
| LTM Sep 2026 | 0.8% | -2.7 pp | -2.1 pp | |
| LTM Jun 2026 | -0.7% | +1.9 pp | +18.6 pp | |
| LTM Jun 2026 | -1.4% | -4.0 pp | -5.5 pp | |
| Peer median (excluding OSCR) | 1.6% | -0.4 pp | -1.6 pp | |
Competitors are the stored peer set for OSCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.92B | 4.13B | 5.86B | 9.18B | 11.7B |
| Cost of Revenue | 0 | 0 | 4.64B | 7.33B | 10.02B |
| Gross Profit | 1.92B | 4.13B | 1.22B | 1.84B | 1.68B |
| Gross Margin | 100.0% | 100.0% | 20.8% | 20.1% | 14.4% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 265.08M | 1.42B | 0 | 0 | 2.05B |
| Operating Expenses | 2.49B | 4.74B | 1.46B | 1.79B | 2.08B |
| Depreciation & Amortization | 14.61M | 15.28M | 30.69M | 32.15M | 28.89M |
| EBITDA | (551.26M) | (572.17M) | (212M) | 89.31M | (391.05M) |
| EBITDA Margin | -28.7% | -13.9% | -3.6% | 1.0% | -3.3% |
| Operating Income | (570.58M) | (610.08M) | (235.62M) | 57.27M | (396.36M) |
| Operating Margin | -29.7% | -14.8% | -4.0% | 0.6% | -3.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.72M | 22.62M | 24.6M | 23.73M | 17.6M |
| Other Income / Expenses | 0 | 0 | (31.69M) | (23.84M) | (40.94M) |
| Income Before Tax | (570.58M) | (610.08M) | (267.3M) | 33.43M | (437.3M) |
| Pre-Tax Margin | -29.7% | -14.8% | -4.6% | 0.4% | -3.7% |
| Income Tax Expense | 846K | (523K) | 3.29M | 7.31M | 5.61M |
| Net Income | (572.61M) | (606.28M) | (270.73M) | 25.43M | (443.15M) |
| Net Margin | -29.8% | -14.7% | -4.6% | 0.3% | -3.8% |
| EPS (Basic) | (3.19) | (2.85) | (1.22) | 0.11 | (1.69) |
| EPS (Diluted) | (3.19) | (2.85) | (1.22) | 0.10 | (1.69) |
| Weighted Avg Shares | 178.97M | 212.47M | 221.66M | 240.39M | 262.39M |
| Weighted Avg Shares (Diluted) | 178.97M | 212.47M | 221.66M | 265.85M | 262.39M |
Oscar Health, Inc.
NYSE:OSCR
Intrinsic Alpha fair value
Locked
Current Price
$27.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.